VEGFA and COVID-19: Based on the crucial role of VEGF in pulmonary edema and inflammation upon SARS‐CoV‐2 infection in the lung, a clinical trial has made its successful debut in treating severe lung injury of COVID‐19 patients by targeting VEGF with Bevacizumab (Pang et al, 2021).